Clinical trials: sponsored by Hutchmed
- Lead sponsor (exact) Hutchmed
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Solid Tumor, Lymphoma
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of surufatinib, thereby identifying the Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of surufatinib administered in combination with…
- Conditions
- Solid Tumor, Lymphoma, Osteosarcoma, Ewing Sarcoma
- Trial name
- NCT05093322
- Testing
- Surufatinib in combination with Gemcitabine
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- Hutchmed
Neuroendocrine Tumors
Expanded Access Program of Surufatinib
This treatment protocol is intended to provide early access of surufatinib to patients with locally advanced or metastatic NETs for whom, in the opinion of their treating physician, other treatment options or surufatinib clinical…
- Trial name
- NCT04814732
- Testing
- Surufatinib
- Where
- 11 sites in United States
- Sponsor
- Hutchmed
Patient Safety
A Phase IV Study of Elunate® (Fruquintinib) in Chinese Patients
A phase IV study to characterize safety of Elunate® (Fruquintinib) in Chinese patients
- Trial name
- NCT04005066
- Testing
- Elunate®
- Where
- China
- Volunteers
- 3,005 people
- Sponsor
- Hutchmed